Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

• ClinicalTrials.gov Identifier: NCT02207621
• Recruitment Status: Completed
• First Posted: August 4, 2014
• Results First Posted: April 6, 2018
• Last Update Posted: April 6, 2018
• Sponsor: Aerie Pharmaceuticals
• Information provided by (Responsible Party): Aerie Pharmaceuticals

Study Description

Brief Summary:

Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution

Condition or disease	Intervention/treatment	Phase
Ocular Hypertension; Open-angle Glaucoma	Drug: AR-13324 Ophthalmic Solution 0.02%; Drug: Timolol maleate Ophthalmic Solution 0.5% BID; Other: Placebo; Drug: AR-13324 Ophthalmic Solution 0.02% BID	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 756 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% q.d. and b.i.d. Compared to Timolol Maleate Ophthalmic Solution, 0.5% b.i.d. in Patients With Elevated Intraocular Pressure
• Actual Study Start Date: July 2014
• Actual Primary Completion Date: March 2016
• Actual Study Completion Date: March 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: AR-13324 Ophthalmic Solution 0.02% & placebo; 1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)	Drug: AR-13324 Ophthalmic Solution 0.02%; 1 drop once daily (QD), PM, OU; Other Name: Netarsudil; Other: Placebo; 1 drop QD, AM, OU
Active Comparator: Timolol maleate Ophthalmic Solution 0.5% BID; 1 drop twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)	Drug: Timolol maleate Ophthalmic Solution 0.5% BID; 1 drop BID, AM/PM, OU
Experimental: AR-13324 Ophthalmic Solution 0.02% BID; 1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)	Drug: AR-13324 Ophthalmic Solution 0.02% BID; 1 drop BID, AM/PM, OU; Other Name: Netarsudil

Outcome Measures

Primary Outcome Measures :

1. Intraocular Pressure (IOP) [ Time Frame: 3 months ]
   The primary efficacy outcome is mean intraocular pressure (IOP)

Secondary Outcome Measures :

1. Extent of Exposure [ Time Frame: 12 Months ]
   Exposure to study medication in days for all treatment groups

Eligibility Criteria

• Ages Eligible for Study: up to 99 Years (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Subject inclusion criteria

1. 0-2 years of age and 18 years or greater
2. Diagnosis of open angle glaucoma or ocular hypertension
3. Unmedicated (post-washout) intraocular pressure (IOP) >20 mm Hg and < 27 mm Hg in the study eye at 2 qualification visits
4. Corrected visual acuity in each eye equivalent to 20/200
5. Able and willing to give signed informed consent (parent or guardian consent for pediatric patient) and follow study instructions

Subject exclusion criteria

Ophthalmic:

1. Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable.
2. Intraocular pressure ≥27 mm Hg (unmedicated) in both eyes or use of more than two ocular hypotensive medications within 30 days of screening. Note: fixed dose combinations count as two medications.
3. Known hypersensitivity to any component of the formulations to be used (benzalkonium chloride, etc.), to topical anesthetics or beta-adrenoceptor antagonists.
4. Previous glaucoma intraocular surgery or glaucoma laser procedures in either eye
5. Refractive surgery in either eye.
6. Ocular trauma in either eye within the six months prior to screening, or ocular surgery or non-refractive laser treatment within the three months prior to screening.
7. Recent or current evidence of ocular infection or inflammation in either eye. Current evidence of clinically significant blepharitis, conjunctivitis, or a history of herpes simplex or zoster keratitis at screening in either eye.
8. Ocular medication in either eye of any kind within 30 days of screening.
9. Clinically significant ocular disease in either eye (e.g., corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe.
10. Central corneal thickness in either eye greater than 600 µm at screening.

11. Any abnormality in either eye preventing reliable applanation tonometry of either eye.

    Systemic:

12. Clinically relevant abnormalities (as determined by the investigator) in laboratory tests at screening which may impact the study.
13. Known hypersensitivity or contraindication to beta-adrenoceptor antagonists (e.g., chronic obstructive pulmonary disease or bronchial asthma; abnormally low blood pressure or heart rate; second or third degree heart block or congestive heart failure; severe diabetes).
14. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
15. Participation in any investigational study within 30 days prior to screening.
16. Changes of systemic medication that could have an effect on intraocular pressure within 30 days prior to screening, or anticipated during the study.
17. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study..

Contacts and Locations

Locations

United States, New Jersey

Aerie Pharmaceuticals

Bedminster, New Jersey, United States, 07921

Sponsors and Collaborators

Aerie Pharmaceuticals

Investigators

• Study Director: Theresa Heah, MD; Aerie Pharmaceuticals, Inc.

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mundorf T, Mah F, Sheng H, Heah T. Effects of Netarsudil on the Corneal Endothelium: Three-Month Findings from a Phase 3 Trial. Ophthalmol Glaucoma. 2020 Nov - Dec;3(6):421-425. doi: 10.1016/j.ogla.2020.04.014. Epub 2020 Apr 29.

• Responsible Party: Aerie Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT02207621
• Other Study ID Numbers: AR-13324-CS302
• First Posted: August 4, 2014
• Results First Posted: April 6, 2018
• Last Update Posted: April 6, 2018
• Last Verified: January 2018

Keywords provided by Aerie Pharmaceuticals:

Glaucoma

Additional relevant MeSH terms:

Glaucoma; Glaucoma, Open-Angle; Ocular Hypertension; Hypertension; Vascular Diseases; Cardiovascular Diseases; Eye Diseases; Timolol; Pharmaceutical Solutions; Ophthalmic Solutions; Adrenergic beta-Antagonists; Adrenergic Antagonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Physiological Effects of Drugs; Anti-Arrhythmia Agents; Antihypertensive Agents